Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Swiss National Bank

Swiss National Bank lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 1.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 51,200 shares of the company's stock after selling 600 shares during the period. Swiss National Bank owned 0.18% of Medpace worth $15,600,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Whittier Trust Co. grew its stake in Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after buying an additional 35 shares during the last quarter. Assetmark Inc. grew its stake in Medpace by 24.9% during the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after buying an additional 43 shares during the last quarter. Proficio Capital Partners LLC grew its stake in Medpace by 6.4% during the 1st quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock worth $237,000 after buying an additional 47 shares during the last quarter. Park Avenue Securities LLC grew its stake in Medpace by 1.8% during the 1st quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock worth $838,000 after buying an additional 48 shares during the last quarter. Finally, Schulhoff & Co. Inc. grew its stake in Medpace by 1.9% during the 1st quarter. Schulhoff & Co. Inc. now owns 2,680 shares of the company's stock worth $817,000 after buying an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. William Blair restated a "market perform" rating on shares of Medpace in a research note on Wednesday, July 23rd. Barclays raised their price target on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. UBS Group downgraded Medpace from a "neutral" rating to a "sell" rating and lifted their target price for the company from $300.00 to $305.00 in a research note on Tuesday, July 29th. Mizuho lifted their target price on Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Finally, TD Cowen reiterated a "sell" rating and issued a $366.00 target price (up from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $406.60.

Medpace Price Performance

Medpace stock opened at $468.00 on Thursday. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $501.30. The company has a market cap of $13.15 billion, a PE ratio of 34.80, a price-to-earnings-growth ratio of 2.89 and a beta of 1.42. The stock's 50 day moving average price is $356.35 and its 200 day moving average price is $329.70.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%. The firm had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same period in the previous year, the business earned $2.75 earnings per share. The company's revenue for the quarter was up 14.2% compared to the same quarter last year. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Transactions at Medpace

In related news, CEO August J. Troendle sold 48,487 shares of Medpace stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $451.69, for a total value of $21,901,093.03. Following the sale, the chief executive officer directly owned 962,615 shares in the company, valued at $434,803,569.35. The trade was a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Kevin M. Brady sold 12,000 shares of the company's stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total value of $5,450,760.00. Following the completion of the sale, the chief financial officer directly owned 6,000 shares in the company, valued at $2,725,380. This trade represents a 66.67% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 112,788 shares of company stock valued at $51,018,354. 20.30% of the stock is owned by company insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.